文献速递泌尿生殖与妇科肿瘤放疗

IB2至IIIB局部晚期宫颈癌:十年经验报告

From IB2 to IIIB locally advanced cervical cancers: report of a ten-year experience.
PubMed 文献 · Radiat Oncol · 2018-02-02

结果显示仅43.6%的患者接受了推荐的标准治疗,5年总生存率为61.9%(95%CI=52.3-73.2),5年疾病特异性生存率为68.5%(95%CI=59.2-79.2)。多因素分析确定体能状态差、淋巴结转移和未接受同步化疗为不良预后因素。

要点

  • 仅43.6%的患者接受了推荐的标准治疗(同步放化疗至少5周期化疗序贯近距离治疗)。
  • 5年总生存率为61.9%(95%CI=52.3-73.2),5年疾病特异性生存率为68.5%(95%CI=59.2-79.2)。
  • 体能状态差、淋巴结转移和未接受同步化疗是不良预后因素。

核心结论

  • 不到50%的局部晚期宫颈癌患者接受了标准治疗,治疗裁剪在日常临床实践中常见。

主要发现

  • 肿瘤FIGO分期:10.6% IB2,22.3% IIA,51.0% IIB,4.3% IIIA,11.7% IIIB;34.0%盆腔淋巴结受累。
  • 所有患者均接受放疗,39.4%采用调强放疗或容积旋转调强放疗;68.1%接受同步顺铂化疗;77.7%接受近距离治疗。
  • 43.6%接受了推荐的标准治疗(同步放化疗至少5周期化疗序贯近距离治疗),中位总治疗时间56天。
  • 完全肿瘤灭活率55.2%,局部复发率18.1%;中位随访54.3个月。

关键数值与推荐

  • 推荐的标准治疗定义为同步放化疗(放疗期间至少5周期化疗)序贯近距离治疗。

临床怎么用

  • 局部晚期宫颈癌患者和疾病具有异质性,治疗裁剪在日常实践中常见,但缺乏裁剪管理的指南。
  • 需要更多真实世界数据以优化临床试验的目标和设计,并使其可转化至日常临床实践。

局限性

  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite screening campaigns, cervical cancers remain among the most prevalent malignancies and carry significant mortality, especially in developing countries. Most studies report outcomes of patients receiving the usual standard of care. It is possible that these selected patients may not correctly represent patients in a real-world setting, which may be a limitation in interpreting outcomes. This study was undertaken to identify prognostic factors, management strategies and outcomes of locally advanced cervical cancers (LACC) treated in daily clinical practice. METHODS: Medical files of all consecutive patients treated with curative intent for LACC in a French Cancer Care Center between 2004 and 2014 were reviewed retrospectively. RESULTS: Ninety-four patients were identified. Performance status was ≥ 2 in 10.6%. Median age at diagnosis was 63.0. Based on the International Federation of Gynecology and Obstetrics classification, tumours were classified as follows: 10.6% IB2, 22.3% IIA, 51.0% IIB, 4.3% IIIA and 11.7% IIIB. Pelvic lymph nodes were involved in 34.0% of cases. Radiotherapy was delivered for all patients. Radiotherapy technique was intensity modulated radiation therapy or volumetric modulated arc therapy in 39.4% of cases. A concurrent cisplatin chemotherapy was delivered in 68.1% of patients. Brachytherapy was performed in 77.7% of cases. The recommended standard care (concurrent chemoradiotherapy with at least five chemotherapy cycles during radiotherapy, followed by brachytherapy) was delivered in 43.6%. The median overall treatment time was 56 days. Complete tumour sterilisation was achieved in 55.2% of cases. Mean follow-up was 54.3 months. Local recurrence rate was 18.1%. Five-year overall survival was 61.9% (95% Confident Interval (CI) = 52.3-73.2) and five-year disease-specific survival was 68.5% (95% CI = 59.2-79.2). Poor performance status, lymph nodes metastasis and absence of concurrent chemotherapy were identified as poor prognostic factors in multivariate analysis. CONCLUSIONS: Less than 50% of patients received the standard care. Because LACC patients and disease are heterogeneous, treatment tailoring appears to be common in current clinical practice. However, guidelines for tailoring management are not currently available. More data about real-world settings are required in order to to optimise clinical trials' aims and designs, and make them translatable in daily clinical practice. TRIAL REGISTRATION: retrospectively registered.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Espenel S, Garcia MA, Trone JC, et al. From IB2 to IIIB locally advanced cervical cancers: report of a ten-year experience. Radiat Oncol. 2018. PMID: 29394940. doi:10.1186/s13014-018-0963-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。